Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 7/20 | 0.71 |
| ▸ | BACE1 | P56817 | 3/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 6/20 | 0.53 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29652026 | 1.00 | APP (0.71) | APPBACE1PTPN1MAOBIMPDH2 | |
| SCHEMBL5527841 | 1.00 | APP (0.71) | APPBACE1PTPN1MAOBIMPDH2 | |
| SCHEMBL29381442 | 1.00 | APP (0.71) | APPBACE1PTPN1MAOBIMPDH2 | |
| SCHEMBL31294294 | 1.00 | APP (0.71) | APPBACE1PTPN1MAOBIMPDH2 | |
| SCHEMBL29378933 | 1.00 | APP (0.71) | APPBACE1PTPN1MAOBIMPDH2 | |
| SCHEMBL18093398 | 1.00 | APP (0.71) | APPBACE1PTPN1MAOBIMPDH2 | |
| SCHEMBL29928591 | 1.00 | APP (0.71) | APPBACE1PTPN1MAOBIMPDH2 | |
| SCHEMBL18093396 | 1.00 | APP (0.71) | APPBACE1PTPN1MAOBIMPDH2 | |
| SCHEMBL4472765 | 1.00 | APP (0.71) | APPBACE1PTPN1MAOBIMPDH2 | |
| SCHEMBL4472768 | 1.00 | APP (0.71) | APPBACE1PTPN1MAOBIMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021148-A1 | METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-01-22 | — | — | US | disclosed |
| US-12318413-B2 | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-06-03 | — | — | US | disclosed |
| US-12310996-B2 | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2025040108-A1 | TRAINING RANDOM FOREST MODEL USING FECAL BIOMARKERS FOR ASSESSING AUTISM SPECTRUM DISORDER | MICROBIOTA I-CENTER (MAGIC) LIMITED (CN) | 2025-02-27 | — | — | WO | disclosed |
| US-20240173361-A1 | METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-30 | — | — | US | disclosed |
| US-20230109343-A1 | METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-06 | — | — | US | disclosed |
| US-11395838-B2 | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-07-26 | — | — | US | disclosed |
| US-20220128556-A1 | METHODS OF DIAGNOSING DISEASE | 4D Pharma Cork Limited (IE) | 2022-04-28 | — | — | US | disclosed |
| US-20220081708-A1 | DIAGNOSIS AND TREATMENT OF DYSBIOSIS-ASSOCIATED WITH NEC | Infinant Health, Inc | 2022-03-17 | — | — | US | disclosed |
| EP-3947743-A1 | METHODS OF DIAGNOSING DISEASE | 4D Pharma Cork Limited (IE) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021148-A1 | METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME | PDCD1, CD274, PDCD1LG2 | APP 2726/4885BACE1 3361/4885PTPN1 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.